Literature DB >> 7558120

The induction of respiratory syncytial virus-specific cytotoxic T-cell responses following immunization with a synthetic peptide containing a fusion peptide linked to a cytotoxic T lymphocyte epitope.

S C Hsu1, D M Shaw, M W Steward.   

Abstract

Previously published work has shown that a cytotoxic T-cell epitope (CTL) representing residues 82-90 of the M2 protein of respiratory syncytial virus (RSV) is the target for a protective response against the virus. In this report, we demonstrate that a synthetic peptide representing residues 81-95, when covalently linked to a fusion peptide derived from the conserved N-terminal 19 residues of the F1 protein of measles virus efficiently primes RSV-specific CTLs in vivo following immunization without adjuvant.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7558120      PMCID: PMC1383905     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine.

Authors:  K Deres; H Schild; K H Wiesmüller; G Jung; H G Rammensee
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

Review 2.  Antigen recognition by class I-restricted T lymphocytes.

Authors:  A Townsend; H Bodmer
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

3.  Introduction of soluble protein into the class I pathway of antigen processing and presentation.

Authors:  M W Moore; F R Carbone; M J Bevan
Journal:  Cell       Date:  1988-09-09       Impact factor: 41.582

4.  Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity of proteolytic cleavage of an inactive precursor protein of Sendai virus.

Authors:  A Scheid; P W Choppin
Journal:  Virology       Date:  1974-02       Impact factor: 3.616

5.  Cooperation between helper T cells and cytotoxic T lymphocyte precursors.

Authors:  L A Husmann; M J Bevan
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

6.  Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.

Authors:  M Shirai; C D Pendleton; J Ahlers; T Takeshita; M Newman; J A Berzofsky
Journal:  J Immunol       Date:  1994-01-15       Impact factor: 5.422

7.  Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs.

Authors:  H Takahashi; T Takeshita; B Morein; S Putney; R N Germain; J A Berzofsky
Journal:  Nature       Date:  1990-04-26       Impact factor: 49.962

8.  Prediction of a putative fusion peptide in the S protein of hepatitis B virus.

Authors:  I Rodríguez-Crespo; J Gómez-Gutiérrez; M Nieto; D L Peterson; F Gavilanes
Journal:  J Gen Virol       Date:  1994-03       Impact factor: 3.891

9.  Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus.

Authors:  A B Kulkarni; P L Collins; I Bacik; J W Yewdell; J R Bennink; J E Crowe; B R Murphy
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

10.  Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo.

Authors:  F R Carbone; M J Bevan
Journal:  J Exp Med       Date:  1990-02-01       Impact factor: 14.307

View more
  2 in total

1.  Phage-displayed T-cell epitope grafted into immunoglobulin heavy-chain complementarity-determining regions: an effective vaccine design tested in murine cysticercosis.

Authors:  K Manoutcharian; L I Terrazas; G Gevorkian; G Acero; P Petrossian; M Rodriguez; T Govezensky
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes.

Authors:  Wai-Ping Woo; Tracy Doan; Karen A Herd; Hans-Jürgen Netter; Robert W Tindle
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.